Ikaria receives Class I notice for drug delivery system recall
This article was originally published in Clinica
Biotherapeutics firm Ikaria has been given a Class I notification from the US FDA after it recalled its Inomax DS drug delivery system. During ongoing review processes the firm discovered that a component within the pressure switch of the system is prone to tearing. This could cause worsening of low blood oxygen, low blood pressure and/or an increase in pulmonary arterial pressure, and death. The company informed customers of the fault on 21 July. The recall affects products distributed from 20 August 2007 to 15 July 2010 and is in effect in the US and Canada. The Clinton, New Jersey-based firm has begun to replace the systems. The Inomax DS system is designed to deliver nitric oxide to patients to help them breathe.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals